CELLAVISION AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 262 SEK | -6.26% |
|
+3.15% | +23.58% |
| 05-03 | CellaVision AB Approves the Dividend, Payable on 13 May 2024 | CI |
| 04-25 | Transcript : CellaVision AB, Q1 2024 Earnings Call, Apr 25, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 782M 74.44M 5.84B | Sales 2025 * | 889M 84.54M 6.63B | Capitalization | 6.25B 595M 46.63B |
|---|---|---|---|---|---|
| Net income 2024 * | 172M 16.36M 1.28B | Net income 2025 * | 217M 20.64M 1.62B | EV / Sales 2024 * | 7.81 x |
| Net cash position 2024 * | 138M 13.1M 1.03B | Net cash position 2025 * | 212M 20.2M 1.58B | EV / Sales 2025 * | 6.79 x |
| P/E ratio 2024 * |
36.5
x | P/E ratio 2025 * |
28.8
x | Employees | - |
| Yield 2024 * |
0.94% | Yield 2025 * |
1.15% | Free-Float | 82.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on CellaVision AB
More press releases
| 1 day | -6.26% | ||
| 1 week | +3.15% | ||
| 1 month | +15.16% | ||
| 3 months | +2.34% | ||
| 6 months | +48.53% | ||
| Current year | +23.58% |
1 week
253.50
282.50
1 month
224.50282.50
Current year
185.20282.50
1 year
120.00282.50
3 years
120.00503.50
5 years
120.00503.50
10 years
21.50503.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 15/11/94 | |
Simon Ostergaard
CEO | Chief Executive Officer | 53 | 20/03/21 |
Magnus Blixt
DFI | Director of Finance/CFO | 58 | 01/05/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 15/11/94 | |
Lotta Jarleryd
BRD | Director/Board Member | 58 | 10/05/22 |
Mikael Worning
CHM | Chairman | 62 | 22/04/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 262 | -6.26% | 64,950 |
| 30/05/24 | 279.5 | +3.14% | 40,995 |
| 29/05/24 | 271 | +2.85% | 41,536 |
| 28/05/24 | 263.5 | +3.33% | 17,241 |
| 27/05/24 | 255 | +0.39% | 10,147 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 04:29 pm
More quotes
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision ABâs product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Calendar
19/07/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
262
SEK
Average target price
257.5
SEK
Spread / Average Target
-1.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.58% | 593M | |
| -27.52% | 16.33B | |
| -40.04% | 2.96B | |
| +15.16% | 1.82B | |
| -6.86% | 1.55B | |
| +38.67% | 1.41B | |
| -15.36% | 976M | |
| -26.08% | 846M | |
| +3.53% | 811M | |
| -24.63% | 631M |
- Stock Market
- Equities
- CEVI Stock
